Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease [Yahoo! Finance]
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Yahoo! Finance
Prasinezumab continues to be well tolerated and no new safety signals were observed Roche is further evaluating the data and will work together with health authorities to determine next steps DUBLIN, December 19, 2024 BUSINESS WIRE )--Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase IIb PADOVA study conducted by partner Roche investigating prasinezumab in 586 people with early-stage Parkinson's disease, treated for a minimum of 18 months while on stable symptomatic treatment. Prasinezumab showed potential clinical effect in the primary endpoint of time to confirmed motor progression with a HR=0.84 [0.69-1.01] and p=0.0657. The effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 [0.63-0.99] and nominal p=0.0431. Pre-specified supplementary covariate-adjusted* analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81 [
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- Prothena Co. plc (NASDAQ: PRTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock, down previously from $84.00.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $40.00 price target on the stock.MarketBeat
- Prothena Co. plc (NASDAQ: PRTA) had its price target lowered by analysts at Bank of America Co. from $26.00 to $22.00. They now have a "neutral" rating on the stock.MarketBeat
- Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug [Seeking Alpha]Seeking Alpha
- Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s DiseaseBusiness Wire
PRTA
Earnings
- 11/12/24 - Beat
PRTA
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form SC
- 11/13/24 - Form SC
- PRTA's page on the SEC website